Roche Commits to $50B in U.S. Manufacturing and R&D Investments as Pharma Tariffs Loom
Roche is pledging to invest $50 billion in manufacturing and research infrastructure in the U.S. over the next five years, ...
Thursday, May 1, 2025
Tag: pharma
Trump signs healthcare executive order that includes a win for pharma companies
By Ahmed AbouleneinWASHINGTON (Reuters) - U.S. President Donald Trump directed his health department on Tuesday to work with Congress on ...
Market in a phase of time correction; recovery to be gradual: Sanjay H Parekh
"It is a very-very good liquidity provision they have done. Now, followed up with another repo rate cut and changing ...
Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s
Novo Nordisk has been on the hunt for differentiated obesity drugs that could complement its blockbuster GLP-1 agonist, Wegovy. It’s ...
Novartis Nabs First FDA Nod in Rare Kidney Disease, But Apellis Pharma Is on Its Heels
An ultra-rare kidney disease that can become life-threatening now has its first FDA-approved therapy. The affirmative regulatory decision is the ...
First-in-Class Brain Cancer Drug Strikes a Chord With Jazz Pharma to the Tune of a $935M M&A Deal
Brain cancers are notoriously difficult to treat, with surgery and radiation continuing to be the main options for these malignancies. ...
Astellas Pharma Inc. 2024 Q3 – Results – Earnings Call Presentation
This article was written byFollowSeeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We ...
Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma
Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is ...
Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer
An Astellas Pharma drug designed to address a novel target has landed a highly anticipated FDA approval for a rare ...
Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition
Neuroscience drug developer Lundbeck is expanding its scope to epilepsy via the $2.6 billion acquisition of Longboard Pharmaceuticals, a company ...
Explore Israel's diverse narratives with The Israel Chronicle. Stay informed with unbiased reporting, insightful analysis, and comprehensive coverage of politics, culture, technology, and more. Discover the heartbeat of Israel through our trusted news platform.